Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

the choice of the adult FAP patient population, selection of cohort size, the dosing regimen, and duration of treatment. The trial is designed to determine safety and tolerability of CEQ508, starting with a dose-escalation phase in which patients will be given one of four escalating concentrations of the drug, contingent upon safety monitoring. This initial part of the clinical trial is expected to take approximately six months. Next, following a safety review, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. The FDA will permit daily dosing of 18 or more patients for 28 days. A key readout and secondary objective of the trial includes analysis of biomarker beta-catenin expression changes in the gastrointestinal tract of patients determined from biopsy samples obtained prior to taking the drug and at the end of the dosing period.

Cequent's Vice President of Drug Development, Alison Silva, commented, "I want to commend the reviewers at CBER who have been very responsive, providing critical feedback immediately following our submission and throughout the application process. They worked with us so that we could address their questions quickly and effectively to reach a successful conclusion by our action date."

With the FDA approval of Cequent's clinical-trial protocol now in hand, the company has begun working with the proposed clinical center to obtain the necessary institutional approvals. Cequent expects to begin the Phase I clinical trial during the first quarter of 2010 at the Fred Hutchinson Cancer Research Center in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium. The Cancer Consortium maintains a registry of FAP patients and is also one of 40 National Cancer Institute-designated comprehensive cancer centers nationwide. Gideon Steinbach, M.D., Ph.D., is slated to be the principal investigator (PI) of the Cequent trial. Dr. Steinbach is
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014 EHE ... exams with a nationwide physician network, today announced that ... has been named an EHE-certified preventive care center. Through ... Tarzana region now have greater access to ... "EHE is proud to add Dr. Abrams ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... Newport Corporation (Nasdaq: NEWP ) today announced that it has ... to Dynasil Corporation (OTC Bulletin Board: DYSL), a provider of technology, ... markets. , , ... Hilger, based in Margate, UK, manufactures and sells a variety of ...
... N.Y. , July 20 As of ... standards applicable to devices that measure A1C (or glycated ... (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C ... SELFCHECK devices, submits for annual NGSP certification each June ...
Cached Medicine Technology:Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 2Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 3New Standard of National Glycohemoglobin Standardization Program 2New Standard of National Glycohemoglobin Standardization Program 3
(Date:9/16/2014)... electronic activity monitors hold great promise in helping ... These increasingly sophisticated devices help the wearers improve ... bodily responses. This information is organized into companion ... the large and quickly growing market for these ... Branch at Galveston analyzed 13 of these activity ...
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... Tara Haelle HealthDay ... A new blood test is the first objective scientific way ... The test measures the levels of nine genetic indicators ... could also determine who will respond to cognitive behavioral therapy, ... and could show whether the therapy worked, Northwestern University researchers ...
(Date:9/16/2014)... Oncology (ASTRO) has selected C.M. Charlie Ma, PhD, Professor, ... Director of Medical Physics at Fox Chase Cancer ... members selected to receive the Fellow of ASTRO designation ... September 16, at the ASTRO,s 56th Annual Meeting in ... is a great honor and we are thrilled that ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... Cancer Center, New York, and colleagues conducted a systematic ... harms of low-dose computerized tomography (LDCT) screening for lung ... "Most patients are diagnosed with advanced disease, resulting in ... "Renewed enthusiasm for lung screening arose with the advent ...
... - Treatment of obstructive sleep apnea (OSA) in children ... and executive function, according to a new study. ... in attention, cognition, and executive function," said lead author ... Sleep Center and University of Colorado Denver. "Our study ...
... More than 4.7 million Americans are bitten by dogs each ... than age 14, experts say. During National Dog Bite ... Pediatrics is joining with the American Veterinary Medical Association and ... They offer many tips to help parents protect their ...
... FRIDAY, May 18 (HealthDay News) -- One-third of homeless people in ... general population, a new study finds. It might seem that ... for weighing too little, according to the researchers at Harvard Medical ... Kingdom. But, the high rate of obesity among homeless people ...
... Since Sept. 11, it has become increasingly common ... or "infidels" to hell, but this has never ... State University professor who recently published a first-of-its-kind book ... Western writers believe condemnation and dehumanization of non-Muslims make ...
... May 18 (HealthDay News) -- Young people can easily buy ... wide range of advertising and marketing efforts from the alcohol ... the Center on Alcohol Marketing and Youth at the Johns ... alcohol messages, which may contribute to the 4,700 alcohol-related deaths ...
Cached Medicine News:Health News:Low-dose CT screening may benefit individuals at increased risk for lung cancer 2Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Keeping Your Family Safe From Dog Bites 2Health News:One-Third of U.S. Homeless Population Is Obese: Study 2Health News:What does Islam say about the fate of others? 2Health News:Underage Drinkers Can Easily Order Alcohol From the Internet 2
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery powered ... the U.S., ,Enterra™ Therapy is indicated ... vomiting associated with gastroparesis when conventional drug ... symptons for diabetic or idiopathic patients., ...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... OMT test is a single use, qualitative, ... of antibodies to Human Immunodeficiency Virus Type ... human oral,mucosal transudate specimens. It is intended ... the clinical diagnosis of HIV,infection. This test ...
Medicine Products: